Amicus Therapeutics Inc (LTS:0HF9)
$ 9.978 -0.0808 (-0.8%) Market Cap: 2.98 Bil Enterprise Value: 3.18 Bil PE Ratio: 0 PB Ratio: 16.66 GF Score: 81/100

Amicus Therapeutics Inc and ARYA Sciences Acquisition IV Corp to Announce Formation of a Next-Generation Genetic Medicine Company Call Transcript

Sep 29, 2021 / 12:00PM GMT
Release Date Price: $9.85 (-4.90%)
Operator

Good morning, ladies and gentlemen, and welcome to Amicus Therapeutics conference call and webcast. (Operator Instructions) As a reminder, this conference call is being recorded.

I would now like to turn the conference over to your host today, Mr. Andrew Faughnan, Executive Director of Investor Relations. You may begin.

Andrew Faughnan
Amicus Therapeutics, Inc. - Senior Director of IR

Thank you, Catherine. Good morning. Thank you for joining today's conference call. Speaking today, we have John Crowley, Chairman and Chief Executive Officer; and Bradley Campbell, President and Chief Operating Officer. Joining for Q&A will be Daphne Quimi, Chief Financial Officer; Dr. Jeff Castelli, Chief Development Officer; Sébastien Martel, Senior Vice President of Strategy and Business Development; and Dr. Jill Weimer, Chief Science Officer.

As referenced on Slide 2, we may make forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our businesses as well as our plans and prospects. Our

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot